<DOC>
	<DOCNO>NCT01422720</DOCNO>
	<brief_summary>This open Label study investigate safety efficacy eslicarbazepine acetate adjunctive therapy partial seizure elderly patient .</brief_summary>
	<brief_title>Safety Efficacy Eslicarbazepine Acetate Adjunctive Therapy Partial Seizures Elderly Patients</brief_title>
	<detailed_description>Multicenter study approximately 100 elderly patient . The study follow open-label design consist 8-week baseline period , follow 26-week treatment period 4-week follow-up period .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>1 . Written inform consent form ; 2 . Of age 65 year old ; 3 . A documented diagnosis epilepsy least 12 month , 4 . At least 2 partialonset seizure ( include subtypes simple partial , complex partial and/or partial seizure evolve secondarily generalise ) 4 week prior screen ; 5 . Currently treat 1 2 AEDs ( except oxcarbazepine ) stable dosage regimen least 4 week prior screen . Vagus nerve stimulation ( VNS ) consider AED ( i.e. , one concomitant AED allow patient VNS ) ; 6 . Willing able comply trial requirement , judgment investigator ; 7 . At least 2 partialonset seizure ( documented diary ) per 4 week 8week baseline period ; 8 . Satisfactorily comply study requirement baseline period 1 . Only simple partial seizure motor symptomatology ( classified A24 ) accord International Classification Epileptic Seizures ) ; 2 . Primarily generalised seizure ; 3 . Known progressive neurological disorder ( progressive brain disease , epilepsy secondary progressive central nervous system lesion ) progressive dementia ; 4 . Occurrence seizure close count accurately ; 5 . History status epileptic cluster seizures 8i.e . 3 seizure within 30 minute ) within 3 month prior screen ; 6 . Seizures nonepileptic origin ; 7 . Major psychiatric disorder ; 8 . History suicide attempt ; 9 . Currently treat oxcarbazepine ; 10 . Previous use ESL participation clinical study ESL ; 11 . Known hypersensitivity carboxamide derivative ( e.g . oxcarbazepine , carbamazepine ) excipients ; 12 . Uncontrolled cardiac , renal , hepatic , endocrine , gastrointestinal , metabolic , haematological oncology disorder , hypo hyper thyroidism type ; 13 . Second thirddegree atrioventricular blockade clinically significant abnormality 12lead electrocardiogram ( ECG ) determine investigator ; 14 . Relevant clinical laboratory abnormality determine investigator ( e.g . plasma sodium &lt; 130 mmol/L , alanine aspartate aminotransferase &gt; 2.0 time upper limit range , white blood cell count &lt; 3,000 cells/mm3 ; 15 . Calculated creatinine value &lt; 30 mL/min screening ; 16 . Any condition circumstance , opinion investigator , may compromise patient 's ability comply study protocol ; 17 . Received investigational drug ( medical device ) within 3 month screen currently participate another trial investigational drug ( medical device ) trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>ESL</keyword>
	<keyword>Eslicarbazepine Acetate</keyword>
	<keyword>BIAL</keyword>
	<keyword>BIA</keyword>
	<keyword>Partial-onset Seizures</keyword>
</DOC>